A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

被引：2

作者：

Mazza, Irit Avivi ^{[1
,2
]}

Barba, Pere ^{[3
]}

Yuda, Junichiro ^{[4
]}

Palomba, Maria Lia ^{[5
]}

Alderuccio, Juan Pablo ^{[6
]}

de Vriendt, Ciel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Jain, Nitin ^{[12
]}

Leonard, Jessica T. ^{[13
]}

Coulson, Michelle ^{[14
]}

Hassounah, Nadia ^{[14
]}

Yang, Xiaoling ^{[14
]}

Lu, Haihui ^{[14
]}

Lewandowski, Andrew ^{[14
]}

Polli, Joseph Ryan ^{[14
]}

Klopfenstein, Matthieu

Pastore, Alessandro ^{[15
]}

Brisou, Gabriel ^{[16
]}

机构：

[1] Tel Aviv Univ, BMT Unit, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[3] Vall DHebron Inst Oncol VHIO, Hosp Univ Vall DHebron, Deparment Hematol, La Garriga, Spain

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Mem Sloan Kettering Canc Ctr, Cellular Therapy Serv, New York, NY USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[7] Univ Hosp Ghent Univ Ziekenhuis, Ghent, Belgium

[8] Univ Milan, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[13] Oregon Hlth & Sci Univ, Dept Med Hematol Oncol, Portland, OR USA

[14] Novartis Inst BioMed Res, Cambridge, MA USA

[15] Novartis Inst BioMed Res, Basel, Switzerland

[16] Inst Paoli Calmettes, Dept Hematol, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy
Bannerji, Rajat
Brown, Jennifer R.
Advani, Ranjana H.
Arnason, Jon
O'Brien, Susan M.
Allan, John N.
Chavez, Julio C.
Barnes, Jeffrey A.
Joyce, Robin
Ansell, Stephen
Topp, Max S.
Adriaens, Lieve
Ufkin, Melanie
Kostic, Ana
Paccaly, Anne
Gao, Bo
Trail, Pamela A.
Lowy, Israel
Brownstein, Carrie
BLOOD, 2016, 128 (22)
[22] Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
Zhu, Haibo
Deng, Haobin
Mu, Juan
Lyu, Cuicui
Jiang, Yanyu
Deng, Qi
ONCOTARGETS AND THERAPY, 2021, 14 : 4023 - 4037
[23] The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
Cao, Jun-Xia
Gao, Wei-Jian
You, Jia
Wu, Li-Hua
Liu, Jin-Long
Wang, Zheng-Xu
CYTOTHERAPY, 2019, 21 (07) : 769 - 781
[24] The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy
Caimi, Paolo F.
Ardeshna, Kirit M.
Reid, Erin
Ai, Weiyun Z.
Lunning, Matthew A.
Zain, Jasmine
Solh, Melhem
Kahl, Brad S.
Hamadani, Mehdi
BLOOD, 2021, 138
[25] Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Davis, James A.
Shockley, Abigail
Glode, Ashley E.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (03) : 686 - 690
[26] b Relapsed and refractory malignant B cell diseases: Evidence for therapeutic efficacy via subcutaneous administration of anti-CD20 x anti-CD3 antibody lymphomun
Buhmann, R.
Ruf, P.
Hess, J.
Lindhofer, H.
Jacob, U.
Dreyling, M.
BONE MARROW TRANSPLANTATION, 2017, 52 : S505 - S505
[27] Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cells
Kochenderfer, James N.
Kassim, Sadik H.
Somerville, Robert
Dudley, Mark E.
Carpenter, Robert O.
Lu, Lily
Feldman, Steven A.
Morton, Kathleen E.
Toomey, Mary Ann
Rosenberg, Steven A.
MOLECULAR THERAPY, 2014, 22 : S295 - S295
[28] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
Yang, Xingcheng
Wei, Jia
Zhou, Jianfeng
HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834
[29] BISPECIFIC ANTIIDIOTYPE ANTI-CD3 ANTIBODY THERAPY OF MURINE B-CELL LYMPHOMA
WEINER, GJ
HILLSTROM, JR
JOURNAL OF IMMUNOLOGY, 1991, 147 (11): : 4035 - 4044
[30] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Jones, Jeffrey A.
Benson, Don M., Jr.
Flynn, Joseph M.
Porcu, Pierluigi
Lustberg, Mark E.
Phelps, Mitchell
Poi, Ming
Chung, Diana
Quinion, Carl
Byrd, John C.
Wegener, William
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2011, 118 (21) : 1584 - 1584

← 1 2 3 4 5 →